Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758671 | 1.00 | HTR1A (0.40) | HTR1ASLC6A4PLGHTR2AHTR2C | |
| SCHEMBL5757030 | 1.00 | HTR1A (0.40) | HTR1ASLC6A4PLGHTR2AHTR2C | |
| SCHEMBL5760433 | 0.89 | HTR1A (0.40) | HTR1ASLC6A4PLGHTR2AHTR2C | |
| SCHEMBL5760437 | 0.89 | HTR1A (0.40) | HTR1ASLC6A4PLGHTR2AHTR2C | |
| SCHEMBL5761298 | 0.89 | HTR1A (0.40) | HTR1ASLC6A4PLGHTR2AHTR2C | |
| SCHEMBL5760384 | 0.86 | HTR1A (0.37) | HTR1ASLC6A4PLGHTR2CCHRNA7 | |
| SCHEMBL7127432 | 0.86 | HTR1A (0.37) | HTR1ASLC6A4PLGHTR2CCHRNA7 | |
| SCHEMBL5760238 | 0.86 | HTR1A (0.37) | HTR1ASLC6A4PLGHTR2CCHRNA7 | |
| SCHEMBL5760244 | 0.86 | HTR1A (0.37) | HTR1ASLC6A4PLGHTR2CCHRNA7 | |
| Hydrochloric Acid SCHEMBL7098171 | 0.85 | HTR1A (0.37) | HTR1ASLC6A4PLGHTR2CCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
| EP-1242411-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046181-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR1A 4/4885SLC6A4 45/4885PLG 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.